'Interim analysis' presentation slideshows

Clinical Trials in Ovarian Cancer

Clinical Trials in Ovarian Cancer. Ovarian Cancer Coalition Regional Conference November 5, 2010. Overview. Preclinical drug development Regulations to protect participants Goals of clinical trials Landmark clinical trials in ovarian cancer

1.1k views • 53 slides

Statistical Issues at FDA

Statistical Issues at FDA. Greg Soon, Ph.D. Statistical Team Leader for Anti-viral Products FDA/CDER/OB/DBIII. 2006.3.2. 3:30-4:30 University of Maryland. Disclaimer. The opinions expressed are those of the author and do not necessarily reflect those of the FDA. Overview.

683 views • 52 slides

Hepatocellular Carcinoma

Hepatocellular Carcinoma. Abby Siegel MD, MS Columbia University Co-Chair, SWOG Hepatobiliary Committee NCI Task Force, Hepatobiliary Cancers. Outline. Epidemiology Biology Staging/Prognosis/Management Future of Targeted Therapy. Outline. Epidemiology Biology

1.06k views • 44 slides

Statistical Analysis Plan and Clinical Study Report

2.16k views • 44 slides

Protocol Development and Statistical Analysis Plans

Protocol Development and Statistical Analysis Plans. Petra Rauchhaus TCTU Clinical Trials Statistician. Importance of the Protocol. Funders. Trialists. Ethics. Journals. Patients. Provide rationale for the trial Define trial goals and processes Define methods of analysis/ reporting

505 views • 33 slides

Protocol Development and Statistical Analysis Plans

Protocol Development and Statistical Analysis Plans. Petra Rauchhaus TCTU Clinical Trials Statistician. Importance of the Protocol. Funders. Trialists. Ethics. Journals. Patients. Provide rationale for the trial Define trial goals and processes Define methods of analysis/ reporting

955 views • 33 slides

Year in Review 2012 Colorectal Cancer

412 views • 29 slides

Experimental Studies

Experimental Studies . Dr Amna Rehana Siddiqui Dr Abdul Aziz Bin Saeed. Objectives. At the end of session students will be able to 1. Explain the design of a Randomized Trial. 2. Justify the methodological issues for, Randomization of intervention & comparison group

434 views • 28 slides

A specialty pharmaceutical company focused on infectious diseases

352 views • 25 slides

Survey of the urgent in-house patient experience whilst waiting for surgery

Survey of the urgent in-house patient experience whilst waiting for surgery. Libby Nolan Cardiothoracic Nurse Practitioner Valerie Meredith Cardiology Nurse Practitioner Aidil Syed Cardiothoracic FP2 Miss F Bhatti Consultant Cardiothoracic Surgeon Mr A Zaidi Consultant Cardiothoracic Surgeon

392 views • 24 slides

Lenalidomide Maintenance after Autologous Transplantation for Myeloma:

564 views • 23 slides

408 views • 21 slides

345 views • 21 slides

291 views • 21 slides

Introduction

341 views • 21 slides

348 views • 17 slides

Kristensen G et al. Proc ASCO 2011;Abstract LBA5006.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer. Kristensen G et al. Proc ASCO 2011;Abstract LBA5006. Background.

182 views • 6 slides

Reviewer: Dr Lori Wood Date posted: June 21, 2007

Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis Authors: Bukowski et al, ASCO 2007. Abstract: 5023. Reviewer: Dr Lori Wood Date posted: June 21, 2007. Treatment A: Sorafenib 400 mg p.o. qd. R. Treatment B:

178 views • 6 slides

Introduction:

Introduction:

63 views • 1 slides

INTRODUCTION

Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/ UGT1A1*1 or UGT1A1*1/ UGT1A1*28 (FFCD 0504 trial) Results of a planned interim analysis.

132 views • 1 slides